Skip to main content

aglatimagene besadenovec

Generic: CAN-2409·Code: CAN-2409

aglatimagene besadenovec: developed by 1 company · 2 clinical trials tracked.

aglatimagene besadenovec evidence translation

What we can confirm

What it means

Source-backed records connect aglatimagene besadenovec to CADL; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could aglatimagene besadenovec → CADL affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Newly diagnosed, localized prostate cancer (intermediate- and high-risk); low-to-intermediate risk localized prostate cancer undergoing active surveillance; stage III/IV non-small cell lung cancer (NSCLC) with inadequate response to PD-(L)1 checkpoint inhibitors; borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).Non-squamous, Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
Candel Therapeutics, Inc. (CADL)
Newly diagnosed, localized prostate cancer (intermediate- an…
Phase 3
Candel Therapeutics, Inc. (CADL)
Non-squamous, Non-Small Cell Lung Cancer; Non Small Cell Lun…
Phase 2
Clinical Trials (2)

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

NCT07660094·Phase 3·CADL
Recruiting

Primary endpoint: Overall Survival

InterventionalRandomizedopen500 targetStarted 2026-06Completion 2031-101 site · United StatesCandel Therapeutics, Inc.

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

NCT04495153·Phase 2·CADL
Active, not recruiting

Primary endpoint: Response rate

Interventionalopen90 enrolledStarted 2020-10Completion 2026-1214 sites · United StatesCandel Therapeutics, Inc.

Frequently asked questions

Who is developing aglatimagene besadenovec?

aglatimagene besadenovec is being developed by Candel Therapeutics, Inc..

How many clinical trials involve aglatimagene besadenovec?

BioSniper tracks 2 clinical trials involving aglatimagene besadenovec.